Lisata Therapeutics, Inc.
LSTA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000320017
No open-market purchases or sales by Lisata Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $3.70M in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Lisata Therapeutics, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- −1 vs. Q2 2024
- Shares held
- 766.2K
- +69.8K (+10.0%) vs. Q2 2024
- Total value
- $2.30M
- −$119.9K (−5.0%) vs. Q2 2024
- New holders
- 2
- 7 more added
- Sold out
- 3
- 4 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LSTA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 31 | $3.70M |
| Q1 2026 | 34 | $7.06M |
| Q4 2025 | 25 | $1.36M |
| Q3 2025 | 21 | $1.93M |
| Q2 2025 | 20 | $2.26M |
| Q1 2025 | 22 | $1.84M |
| Q4 2024 | 21 | $2.33M |
| Q3 2024 | 20 | $2.30M |
| Q2 2024 | 22 | $2.61M |
| Q1 2024 | 21 | $2.30M |
| Q4 2023 | 22 | $2.03M |
| Q3 2023 | 21 | $1.46M |
| Q2 2023 | 22 | $2.51M |
| Q1 2023 | 21 | $2.08M |
| Q4 2022 | 24 | $1.83M |
| Q3 2022 | 22 | $2.17M |
| Q2 2022 | 36 | $5.00M |
| Q1 2022 | 34 | $6.13M |
| Q4 2021 | 36 | $7.33M |
| Q3 2021 | 34 | $9.41M |
| Q2 2021 | 29 | $10.1M |
| Q1 2021 | 33 | $12.9M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Lisata Therapeutics, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BML Capital Management, LLC | 284,669 | $854.0K | 0.50% | 00.0% | Unchanged |
| Vanguard Group Inc | 186,366 | $559.1K | 0.00% | +2,033+1.1% | Added |
| Renaissance Technologies LLC | 103,622 | $310.9K | 0.00% | +2,000+2.0% | Added |
| BlackRock, Inc. | 56,013 | $168.0K | 0.00% | +56,013 | New |
| Geode Capital Management, LLC | 55,681 | $167.1K | 0.00% | +4,783+9.4% | Added |
| Dimensional Fund Advisors LP | 17,340 | $52.0K | 0.00% | +40.0% | Added |
| State Street Corp | 14,348 | $43.0K | 0.00% | 00.0% | Unchanged |
| Cook Wealth Management Group LLC | 12,175 | $34.2K | 0.02% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 11,019 | $33.1K | 0.00% | +11,019 | New |
| HighTower Advisors, LLC | 10,042 | $30.0K | 0.00% | −20.0% | Reduced |
| Bank of America Corp | 9,715 | $29.1K | 0.00% | +20.0% | Added |
| Founders Capital Management | 2,000 | $6.00K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,526 | $4.58K | 0.00% | +1,086+246.8% | Added |
| Morgan Stanley | 1,466 | $4.40K | 0.00% | −1,084−42.5% | Reduced |
| UBS Group AG | 125 | $375 | 0.00% | −3,584−96.6% | Reduced |
| JPMorgan Chase & Co | 15 | $45 | 0.00% | −1−6.3% | Reduced |
| Barclays PLC | 7 | $21 | 0.00% | +3+75.0% | Added |
| Wells Fargo & Company | 1 | $3 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 1 | $3 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 52 | $0 | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 0 | $0 | 0.00% | −1,436−100.0% | Sold out |
| Castleview Partners, LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Steward Partners Investment Advisory, LLC | 0 | $0 | 0.00% | −6−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |